Hepatitis B Virus Covalently Closed Circular DNA Predicts Postoperative Liver Cancer Metastasis Independent of Virological Suppression
Open Access
Abstract
New antiviral therapies against hepatitis B virus (HBV) focus on the elimination of covalently closed circular DNA (cccDNA). However, traditional cccDNA-specific quantitative PCR (qPCR) has a narrow effective range, hindering a reliable comparison between the levels of biopsy-derived cccDNAs. Collaterally, the prognostic role of cccDNA in HBV-related hepatocellular carcinoma (HCC) cannot be clearly defined. Here, we developed a peptide nucleic acid (PNA)-clamping qPCR method to provide a wider range of specific cccDNA quantification (up to 5 logs of effective range). Extrachromosomal DNA was extracted from para-neoplastic tissues for cccDNA quantification. In total, 350 HBV-related HCC patients were included for an outcome analysis. Without differential pre-dilution, cccDNA levels in para-neoplastic liver tissues were determined, ranging from < 2 × 103 to 123.0 × 106 copies/gram. The multivariate linear regression analysis showed that cccDNA was independently correlated with the HBV e antigen (p < 0.001) and serum HBV-DNA levels (p = 0.012). The Cox proportional hazard model analysis showed that cccDNA independently predicted overall survival (p = 0.003) and extrahepatic metastasis-free survival (p = 0.001). In virologically suppressed HCC patients, cccDNA still effectively predicted intrahepatic recurrence-free (p = 0.003) and extrahepatic metastasis-free (p = 0.009) survivals. In conclusion, cccDNA independently predicted postoperative extrahepatic metastasis-free survival.Keywords
Funding Information
- Ministry of Science and Technology, Taiwan (107-2314-B-182-004-MY3; 107-2314-B-182A-109)
- Chang Gung Memorial Hospital, Linkou (CRRPG3F0053; CMRPG3H1441)
This publication has 44 references indexed in Scilit:
- Three-Year Efficacy and Safety of Tenofovir Disoproxil Fumarate Treatment for Chronic Hepatitis BGastroenterology, 2011
- Hepatitis B Virus–DNA Level and Basal Core Promoter A1762T/G1764A Mutation in Liver Tissue Independently Predict Postoperative Survival in Hepatocellular CarcinomaHepatology, 2010
- Hepatitis B virus infectionThe Lancet, 2009
- Meta‐analysis: treatment of hepatitis B infection reduces risk of hepatocellular carcinomaAlimentary Pharmacology & Therapeutics, 2008
- Peptide nucleic acid–locked nucleic acid polymerase chain reaction clamp‐based detection test for gefitinib‐refractory T790M epidermal growth factor receptor mutationCancer Science, 2008
- Quantification of hepatitis B virus covalently closed circular DNA in patients with hepatocellular carcinomaJournal of Hepatology, 2006
- Peginterferon Alfa-2a Alone, Lamivudine Alone, and the Two in Combination in Patients with HBeAg-Negative Chronic Hepatitis BNew England Journal of Medicine, 2004
- Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy1 ☆Gastroenterology, 2004
- Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis BHepatology, 2004
- Sequence-Selective Recognition of DNA by Strand Displacement with a Thymine-Substituted PolyamideScience, 1991